InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,048.42
(
-0.46%
)
US TECH 100
17,166.00
(
1.11%
)
Dow Jones
38,085.80
(
-0.98%
)
Brent Oil
88.06
(
-0.10%
)
Bitcoin
64,381.88
(
-0.16%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 244

Saturday, 07/14/2018 4:50:31 PM

Saturday, July 14, 2018 4:50:31 PM

Post# of 438
APTX 6/18 IPO with two Ph2 trials with the same compound, both reading out H1/19

NYX 925 is being studied for the treatment of Painful Diabetic Neuropathy (DN) AND the treatment of Fibromyalgia.

APTX is also partnered with AGN in a program for Major Depressive Disorder.

FDA has been granted fast track status for the DN program. This market has TAM of over $5.5B , but strong competition.

After the IPO proceeds, the company's cash runway extendes thru 2020.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up